IHM
Iguana Healthcare Management Portfolio holdings
AUM
$133M
This Quarter Return
+15.77%
1 Year Return
+45.66%
3 Year Return
+127.07%
5 Year Return
–
10 Year Return
–
AUM
$175M
AUM Growth
+$175M
(+12%)
Cap. Flow
+$7.09M
Cap. Flow
% of AUM
4.05%
Top 10 Holdings %
Top 10 Hldgs %
36.73%
Holding
79
New
20
Increased
23
Reduced
18
Closed
11
Top Buys
| 1 |
Biogen
BIIB
|
$3.91M |
| 2 |
Bristol-Myers Squibb
BMY
|
$3.51M |
| 3 |
Danaher
DHR
|
$3M |
| 4 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$2.61M |
| 5 |
Esperion Therapeutics
ESPR
|
$2.51M |
Top Sells
| 1 |
SHPG
Shire pic
SHPG
|
$6.61M |
| 2 |
AGN
Allergan plc
AGN
|
$6.08M |
| 3 |
SPNC
Spectranetics Corp
SPNC
|
$4.22M |
| 4 |
Sanofi
SNY
|
$3.59M |
| 5 |
CELG
Celgene Corp
CELG
|
$3.28M |
Sector Composition
| 1 | Healthcare | 80.34% |
| 2 | Financials | 2.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CELG
1
DELISTED
Celgene Corp
CELG
| $10.9M | 5.96% | 75,000 -22,500 | -23% | -$3.28M |
|
|
2
Esperion Therapeutics
ESPR
$448M
| $7.52M | 4.1% | 150,000 +50,000 | +50% | +$2.51M |
|
|
IMMU
3
DELISTED
Immunomedics Inc
IMMU
| $6.99M | 3.81% | 500,000 +175,000 | +54% | +$2.45M |
|
|
CLVS
4
DELISTED
Clovis Oncology, Inc.
CLVS
| $6.59M | 3.59% | 80,000 +5,000 | +7% | +$412K |
|
|
5
Biogen
BIIB
$19.4B
| $6.26M | 3.41% | 20,000 +12,500 | +167% | +$3.91M |
|
6
AbbVie
ABBV
$372B
| $5.78M | 3.15% | 65,000 +25,000 | +63% | +$2.22M |
|
|
ALXN
7
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $5.61M | 3.06% | 40,000 -20,000 | -33% | -$2.81M |
|
8
Cigna
CI
$80.3B
| $4.95M | 2.7% | 26,500 +9,000 | +51% | +$1.68M |
|
|
AERI
9
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $4.86M | 2.65% | 100,000 +5,000 | +5% | +$243K |
|
10
Merck
MRK
$210B
| $4.8M | 2.62% | 75,000 -5,000 | -6% | -$320K |
|
11
Abbott
ABT
$231B
| $4.54M | 2.47% | 85,000 +45,000 | +113% | +$2.4M |
|
|
AET
12
DELISTED
Aetna Inc
AET
| $4.53M | 2.47% | 28,500 -4,000 | -12% | -$636K |
|
13
Karyopharm Therapeutics
KPTI
$61.7M
| $4.39M | 2.39% | 400,000 +100,000 | +33% | +$1.1M |
|
|
KTWO
14
DELISTED
K2M Group Holdings, Inc
KTWO
| $4.24M | 2.31% | 200,000 | – | – |
|
|
GBT
15
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $3.88M | 2.11% | 125,000 -50,000 | -29% | -$1.55M |
|
|
MDCO
16
DELISTED
Medicines Co
MDCO
| $3.7M | 2.02% | 100,000 -50,000 | -33% | -$1.85M |
|
17
Boston Scientific
BSX
$156B
| $3.65M | 1.99% | 125,000 +70,000 | +127% | +$2.04M |
|
18
Zimmer Biomet
ZBH
$21B
| $3.51M | 1.91% | 30,000 +5,000 | +20% | +$586K |
|
|
19
Bristol-Myers Squibb
BMY
$96B
| $3.51M | 1.91% | +55,000 | New | +$3.51M |
|
20
Eli Lilly
LLY
$657B
| $3.42M | 1.86% | 40,000 -10,000 | -20% | -$856K |
|
|
DERM
21
DELISTED
Dermira, Inc.
DERM
| $3.38M | 1.84% | 125,000 -15,000 | -11% | -$405K |
|
|
JUNO
22
DELISTED
Juno Therapeutics, Inc.
JUNO
| $3.37M | 1.83% | 75,000 -25,000 | -25% | -$1.12M |
|
23
Glaukos
GKOS
$5.5B
| $3.3M | 1.8% | 100,000 +40,000 | +67% | +$1.32M |
|
|
TSRO
24
DELISTED
TESARO, Inc.
TSRO
| $3.23M | 1.76% | 25,000 +10,000 | +67% | +$1.29M |
|
|
25
Danaher
DHR
$147B
| $3M | 1.64% | +35,000 | New | +$3M |
|